UPC Considers but does not decide exhaustion of rights in relation to consumables

No items found.
​
October 30, 2025

Brita v. Aquashield

UPC CFI 248/2024 (Munich LD), decision of 22 August 2025[1]

UPC CFI 564/2024 (Munich LD), decision of 16 October 2025[2]

Brita sued Aquashield and others for infringement of EP2387547, which Brita says protects its replaceable water filters (case ref. UPC CFI 248/2024). Aquashield responded with a counterclaim for revocation (case ref. UPC CFI 564/2024).

Aquashield distributes Philips-branded filters that are compatible with Brita's filter system, though they function in a different manner to Brita's own cartridges.

Indirect infringement and exhaustion

The decision of 22 August 2025 in the combined infringement action and counterclaim for revocation includes some interesting discussion in the context of indirect infringement. In particular, discussion of who is a "party entitled to exploit the patented invention" based on exhaustion of rights from sale of a system including consumable parts.

Following the assessment of validity, the surviving independent claim covered a complete filter system, i.e. the combination of a water jug and a filter. Since the defendants supply only the filter, the question of infringement shifted to one of indirect infringement.

One of the criteria for indirect infringement is that the defendant is supplying (or offering to supply) any person other than "a party that is entitled to exploit the patented invention" with means for putting the patented invention into effect[3].

The defendants argued that Brita's authorised sale of the original filter systems exhausted any rights conferred by the patent[4], and that end-users of the defendants' filters are therefore "a party entitled to exploit the invention".

In the decision, the court provides comments on when rights may or may not be exhausted in the context of replacing a consumable part. In particular, the court noted that while proper use of a patent-protected product also includes the normal maintenance and repair, it does not include any measures that result in the reproduction of a product covered by a patent. The question is whether this replacement is permissible use in accordance with the intended purpose of the product, or whether it constitutes an impermissible new manufacture of the product. For consumable parts, replacement is a normal maintenance measure and will generally be a permissible use of the patent-protected product placed on the market unless the invention lies in the replaced part.

Unfortunately, the court did not have to decide the exhaustion issue based on these principles, because the patent as amended does not cover the filter sold by Brita, so Brita had never placed the product on the market in the first place.

Withdrawal of the counterclaim after decision issued

In the end, the court found in Brita's favour, but it may have been a Pyrrhic victory. Brita's patent was limited in a way that the UPC has explicitly stated does not cover Brita's own filter cartridges, potentially leaving the door open for third party direct copies.

The decision of 16 October 2025 was issued after Aquashield applied to withdraw the counterclaim for revocation. The court held that withdrawal after a decision has been issued is permissible within the appeal period, even if an appeal is not filed. The result is that the decision of 22 August is ineffective in so far as it limits Brita's patent, leaving a weakened but still effective moat in place around its filter cartridges.

Withdrawal of the counterclaim suggests that the parties reached a settlement following the decision of 22 August. Perhaps Brita did not have the appetite for an appeal, mirroring the ancient king of Epirus in believing that one more victory over Aquashield could ruin

[1] https://www.unifiedpatentcourt.org/en/node/137240

[2] https://www.unifiedpatentcourt.org/en/node/159547

[3] Article 26 UPCA.

[4] Article 29 UPCA.

The Latest Thought Leadership pieces in the Content Hub

UPC takes strict approach on costs reimbursement
October 30, 2025
Insulet v. EOFlow UPC_CFI_773/2025 and UPC_CFI 774/2025 (Milan CD), decision of 15 October 2025[1] The dispute began when Insulet sought a provisional injunction against EOFlow to prevent...
UPC Infringement Actions: Is Speed Meeting Expectations?
September 23, 2025
The Unified Patent Court promised simplified and faster patent litigation across Europe. Two years in, we look at whether it’s delivering on that promise. For patent holders and defendants alike, the duration of infringement actions can significantly impact market strategies, investment decisions, and competitive positioning. In this article, we set out an in-depth analysis of how the court’s procedural rules are shaping the pace of litigation. By examining key milestones—from the filing of an infringement action to the issuance of a final judgment—we assess whether the UPC is delivering on its promise of efficiency.
Emerging Practice Points from the UPC
September 2, 2025
We have been keeping a close eye on the decisions coming out of the UPC and as the court starts to establish itself a number of practice points are starting to emerge.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
The UPC After Three Years: From Experiment to Enforcement Forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
Inside the Visser AI Launch Party
20 May 2026
EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.
Protecting Your Startup: Five Intellectual Property Mistakes to Avoid
20 May 2026
Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.
Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.